Medical Rescheduling, Recreational Risk: How Schedule III Could Reshape Adult-Use Cannabis
|
Medical Rescheduling, Recreational Risk: How Schedule III Could Reshape Adult-Use Cannabis Article by: Raza Lawrence and Ivy Perez-Bader
After more than fifty years of classification alongside heroin and LSD, cannabis may soon occupy the same legal category as ketamine and Tylenol with codeine. Following an Executive Order issued by President Trump in December 2025 directing the Attorney General to complete the rescheduling rulemaking process in an expeditious manner, reclassification of cannabis as a Schedule III substance under the Controlled Substances Act (CSA) remains under active federal consideration and, if finalized, would represent a significant inflection point for the U.S. cannabis industry. Although the federal tax implications may be substantial, they represent only one component of a broader regulatory realignment. The operational and compliance consequences of Schedule III status warrant equal attention, particularly for adult-use operators, for whom rescheduling may sharpen—rather than reduce—exposure to federal legal risk.
The Tax Shift: What Happens When Section 280E No Longer Applies Section 280E disallows deductions and credits for businesses that “traffic” in controlled substances listed on Schedule I or II of the CSA. Under federal law, that concept of trafficking applies equally to state-licensed dispensaries and illegal drug operations. Although Section 280E would remain on the books following rescheduling, cannabis would no longer fall within its scope if it is moved to Schedule III. The result would be a fundamental change in the federal tax treatment of cannabis businesses.
The timing of that change remains uncertain. The Executive Order directs completion of the rulemaking process already underway following the Department of Justice’s May 2024 proposed rule to reschedule cannabis. That proposal received nearly 43,000 public comments and is currently awaiting an administrative law hearing required under 21 U.S.C. § 811. The hearing requirement cannot be bypassed by executive action, and litigation challenging a final rule could further extend the implementation timeline. Questions also remain regarding the effective date of any final rule and whether rescheduling would apply retroactively for tax-year purposes.
If rescheduling becomes effective, cannabis operators would be permitted to deduct ordinary and necessary business expenses—such as payroll, rent, marketing, and professional services—on the same basis as other lawful businesses. For some operators, the impact could be dramatic. Under current law, a dispensary generating $5 million in annual revenue with $4 million in operating expenses might—in high-margin scenarios—face an effective federal tax rate exceeding 70% because Section 280E disallows deductions for most operating expenses and limits relief largely to cost of goods sold. The business is therefore taxed on income that more closely resembles gross margin than true net profit. Removal of Section 280E would align taxable income more closely with actual economic earnings.
Rescheduling would also substantially reduce reliance on inventory capitalization strategies under Internal Revenue Code § 471. Under the current regime, operators attempt to allocate indirect costs into inventory to mitigate 280E’s disallowance of deductions—a complex and compliance-intensive approach that has generated significant audit exposure and litigation risk. If ordinary deductions are restored, much of this accounting distortion would become unnecessary. Financial reporting would more closely resemble conventional retail or consumer packaged goods models, improving comparability, transparency, and access to institutional debt and equity capital…. Read more |
 |
|
|